ITGAX and rheumatoid arthritis: Consistently, multiple research suggested that several effector cells in the synovial membrane of RA could be potential therapeutic targets, including MERTK+ macrophages 44, NOTCH3+ synovial fibroblasts 45, CD11c+ autoimmune associated B cells 46, and PD-1+ peripheral helper T cells 47, 48.